Search results for "IntelliDrug"
showing 7 items of 7 documents
Current status in buccal drug delivery
2008
This article overviews the progress made in buccal drug delivery research during the last five years and reports a new high-tech approach to achieve controlled delivery.
Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue
2016
Levodopa (l-DOPA) is the most effective pharmacologic agent in Parkinson's disease and remains the "gold standard". Nevertheless, in long-term treatments, dyskinesias and motor complications can emerge. In this work, the combined use of l-DOPA methylester hydrochloride prodrug (LDME) with transbuccal drug delivery was supposed as a good alternative method to optimize the bioavailability of l-DOPA, to maintain constant plasma levels and to decrease the drug unwanted effects. The effects of environmental pH on buccal delivery of LDME were evaluated ex vivo. The increase of pH value from 5.8 to 6.2 implies an improvement of drug permeation. Since the pH increase causes the raising of hydrolyti…
An intraoral drug delivery device for long term therapies: application in Alzheimer’s disease
2009
A new intraoral device to home assist Parkinson’s disease patients by distant control
2009
Ambulante Therapie & Telemonitoring von Patienten mit Parkinson
2011
Körpernahe Sensornetzwerke können schon heute zur Steigerung der Lebensqualität beitragen, indem der Patient sein gewohntes Umfeld nicht zwingend verlassen muss. Der natürliche und nächste Schritt zur Verbesserung dieser wertvollen Diagnosesysteme beruht auf die Einbeziehung körpernaher Aktuatoren, welche auch eine gleichzeitige Therapierung erlauben. Durch einen interdisziplinären Ansatz, der klinische und technologische Erkenntnisse vereint, entsteht ein Sen-sor- und Aktuatornetzwerk, das am Beispiel eines sich in Entwicklung befindlichen innovativen Systems zur Behandlung von Parkinson vorgestellt wird.
Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs.
2010
Naltrexone (NLX), an opioid antagonist, is widely used in the treatment of opiate addiction, alcoholism and smoking cessation. Its current peroral administration induces various adverse side effects and has limited efficacy since bioavailability and patient compliance are poor. The development of a long-acting drug delivery system of NLX may overcome the current drawbacks and help in the improvement of treatment of addiction. The primary endpoints of this study were: a) to compare the NLX bioavailability and pharmacokinetics after delivering a single transbuccal dose, released by a prototype of intraoral device, versus an intravenous (I.V.) bolus of the same drug dose; b) to verify the func…